ISGIO Annual Conference | Conferences

Targeted Agents May Be Moving Closer to Frontline for Treatment of mCRC

October 14, 2019

Treatment targeting molecular pathways such as BRAF, HER2, and RAS has typically been reserved for later lines of therapy for patients with metastatic colorectal cancer. Benjamin A. Weinberg, MD, said that agents targeting these pathways are not yet ready for the upfront setting, but data from ongoing trials suggest that these agents may eventually have a role to play in first- and second-line treatment.

Expert Compares Data for Immunotherapy Versus Chemotherapy In GEJ Cancer

October 14, 2019

In an interview with Targeted Oncology, Daniel Catenacci, MD, discussed the clinical trials supporting immunotherapeutic options for patients with GEJ cancer. He also highlighted how physicians can sequence these agents appropriately in their patients.

Immunotherapy Options Growing for Metastatic Colorectal Cancer

October 14, 2019

Immunotherapeutic agents have grown in popularity for treating mismatch repair–deficient metastatic colorectal cancer, becoming the standard of care in the second line, Howard Hochster, MD, told an audience at the 2019 Gastrointestinal Oncology Conference. Furthermore, ongoing clinical trials suggest that these agents may play a larger role in treating CRC going forward.

Choosing Between Systemic Therapy and TACE for HCC

October 11, 2019

What is the ideal first-line therapy for nonresectable, non–transplantable eligible, liver-only hepatocellular carcinoma? In a debate at the 2019 Gastrointestinal Oncology Conference, Mark Yarchoan, MD, had the unenviable task of convincing the audience that systemic therapy was the way to go.

Neoadjuvant Chemotherapy Prior to Surgery Holds Benefit in Pancreatic Cancer

October 11, 2019

In an interview with Targeted Oncology, Michael A. Choti, MD, MBA discussed the treatment landscape for patients with pancreatic cancer, as well as how the role of neoadjuvant chemotherapy in this space is changing. He highlights advantages of neoadjuvant strategies, and also some other treatment options for patients with pancreatic cancer.

Seeking Answers for Pancreatic Treatment Beyond FOLFIRINOX

October 10, 2019

The FOLFIRINOX regimen remains the treatment of choice for patients with pancreatic cancer even as clinical trials exploring potential therapies, including CD40 and CPI-613, offer the possibility of new options for a notoriously difficult-to-treat disease, Davendra P.S. Sohal, MD, MPH, told an audience at the 2019 Gastrointestinal Oncology Conference.